by Ryan Bangert
The justices will review the FDA’s decision to gut safeguards regarding the use of a chemical-abortion drug.
Share this story
Mifepristone, the first medication in a medical abortion, is prepared for a patient at Alamo Women’s Clinic in Carbondale, Ill., April 20, 2023.
Evelyn Hockstein/Reuters
Over one year has passed since the Supreme Court overturned Roe v. Wade in Dobbs v. Jackson Women’s Health Organization and empowered the people and their elected lawmakers to address the issue of abortion. That tectonic shift has exposed the latent radicalism of the far left’s near-religious commitment to abortion, whatever the cost.
That commitment will now be put to the test before the Supreme Court.
About the Author
Ryan Bangert is the senior vice president of strategic initiatives, and special counsel to the president, for Alliance Defending Freedom (@ADFLegal).
Advertisement
Advertisement
Over one year has passed since the Supreme Court overturned Roe v. Wade in Dobbs v. Jackson Women’s Health Organization and empowered the people and their elected lawmakers to address the issue of abortion. That tectonic shift has exposed the latent radicalism of the far left’s near-religious commitment to abortion, whatever the cost.
That commitment will now be put to the test before the Supreme Court.
By continuing, you agree to our terms of service and privacy policy.
About the Author
Ryan Bangert is the senior vice president of strategic initiatives, and special counsel to the president, for Alliance Defending Freedom (@ADFLegal).
Advertisement
Advertisement
Comments